[go: up one dir, main page]

NO20065719L - Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor. - Google Patents

Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor.

Info

Publication number
NO20065719L
NO20065719L NO20065719A NO20065719A NO20065719L NO 20065719 L NO20065719 L NO 20065719L NO 20065719 A NO20065719 A NO 20065719A NO 20065719 A NO20065719 A NO 20065719A NO 20065719 L NO20065719 L NO 20065719L
Authority
NO
Norway
Prior art keywords
amino
substantially pure
phenylpyridin
indol
pyrimidin
Prior art date
Application number
NO20065719A
Other languages
Norwegian (no)
Inventor
David John Aldous
Olaf Ritzeler
El-Bdaoui Haddad
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20065719L publication Critical patent/NO20065719L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår i det vesentlige ren forbindelse med formel (A) eller farmasøytisk akseptabelt salt eller solvat av nevnte forbindelse; en farmasøytisk sammensetning som innbefatter en farmasøytisk effektiv mengde av forbindelsen med formel (A), og en farmasøytisk akseptabel bærer; og anvendelse av en forbindelse med formel (A) som har aktivitet som en inhibitor, foretrukket en selektiv inhibitor, av I(B (IKK), særlig IKK-2, og fremgangsmåter relatert dertil.The present invention relates to substantially pure compound of formula (A) or pharmaceutically acceptable salt or solvate of said compound; a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier; and the use of a compound of formula (A) having activity as an inhibitor, preferably a selective inhibitor, of I (B (IKK), especially IKK-2, and methods related thereto.

NO20065719A 2004-05-12 2006-12-12 Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor. NO20065719L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
PCT/US2005/016381 WO2005113544A1 (en) 2004-05-12 2005-05-11 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor

Publications (1)

Publication Number Publication Date
NO20065719L true NO20065719L (en) 2006-12-12

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065719A NO20065719L (en) 2004-05-12 2006-12-12 Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor.

Country Status (23)

Country Link
EP (1) EP1747215A1 (en)
JP (1) JP2007537266A (en)
KR (1) KR20070011483A (en)
CN (1) CN1950359A (en)
AR (1) AR049274A1 (en)
AU (1) AU2005245834A1 (en)
BR (1) BRPI0511029A (en)
CA (1) CA2566213A1 (en)
EC (1) ECSP066992A (en)
GT (1) GT200500111A (en)
IL (1) IL178992A0 (en)
MA (1) MA28553B1 (en)
MX (1) MXPA06012870A (en)
NO (1) NO20065719L (en)
PA (1) PA8633101A1 (en)
PE (1) PE20060269A1 (en)
RU (1) RU2006143758A (en)
SV (1) SV2006002111A (en)
TN (1) TNSN06338A1 (en)
TW (1) TW200605881A (en)
UY (1) UY28897A1 (en)
WO (1) WO2005113544A1 (en)
ZA (1) ZA200608712B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE102004033406A1 (en) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (en) 2008-04-21 2022-06-14 Otonomy, Inc. INTRATYMPANIC COMPOSITION INCLUDING BRAIN-DERIVED NEUROTROPHIC GROWTH FACTOR (BDNF) FOR THE TREATMENT OR PREVENTION OF HEARING LOSS
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
RU2552999C2 (en) 2010-04-27 2015-06-10 Хатчисон Медифарма Лимитед Pyrimidine indole compounds
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. TRICLYCERIDE FORMULAS FOR THE EAR AND USE THEREOF
CN106588803A (en) * 2016-11-16 2017-04-26 西南科技大学 Novel method for preparing 5-acetylisoxazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
CA2566213A1 (en) 2005-12-11
IL178992A0 (en) 2007-03-08
MA28553B1 (en) 2007-04-03
ZA200608712B (en) 2008-06-25
PE20060269A1 (en) 2006-05-11
AU2005245834A1 (en) 2005-12-01
ECSP066992A (en) 2006-12-29
AR049274A1 (en) 2006-07-12
KR20070011483A (en) 2007-01-24
JP2007537266A (en) 2007-12-20
WO2005113544A1 (en) 2005-12-01
BRPI0511029A (en) 2007-11-27
CN1950359A (en) 2007-04-18
TW200605881A (en) 2006-02-16
TNSN06338A1 (en) 2008-02-22
UY28897A1 (en) 2005-12-30
PA8633101A1 (en) 2006-01-23
EP1747215A1 (en) 2007-01-31
RU2006143758A (en) 2008-06-27
SV2006002111A (en) 2006-01-30
MXPA06012870A (en) 2007-02-15
GT200500111A (en) 2006-05-09

Similar Documents

Publication Publication Date Title
NO20065719L (en) Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor.
NO20080865L (en) Spirochromanone derivatives such as acetyl-coenzyme-A-carboxylase (ACC) inhibitors
NO20082090L (en) Pyridopyrimidinone inhibitors of P13K alpha
NO20072978L (en) New betuene derivatives, their preparation and their use
SE0400284D0 (en) Novel compounds
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
NO20091858L (en) Hydrobenzamide derivatives as inhibitors of HSP90
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA200702670A1 (en) PREPARATION OF THYENOPYRIDINE INHIBITOR OF PLATELET AGGREGATION
NO20055568L (en) Substituted 1,4-diazepines and uses thereof
DK1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
EA200701745A1 (en) CYCLOPROPANKARCARBOXAMID DERIVATIVES
MX2009010302A (en) Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same.
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
HRP20080027T3 (en) 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID (4-METHOXY-7-MORPHOLIN-4-IL-BENZOTIAZOL-2-IL) -AMIDE
NO20071805L (en) Alkylidentetrahydronaphthalene derivatives, processes for their preparation and their use as inflammatory inhibitors.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200637539A (en) CTGF inhibitors
NO20033130L (en) Use of 2-amino-4-heteroarylethylthiazoline as inhibitors of inducible NO synthase
NO20090332L (en) 4-Amino-3-arylamino-6-arylpyrazole [3,4-D] pyrimidine derivatives, methods of their preparation and use as antiviral agents
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
DK1791537T3 (en) 3-arylthioindole-2-carboxamide derivatives and analogues thereof as inhibitors of casein kinase
EA200600760A1 (en) NEW COMPOUNDS PHENILPYRIDILPIPERAZINE, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO20085215L (en) New pyridine analogs
WO2007000655A3 (en) Novel pyrazolopyrimidinone derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application